Literature DB >> 32026671

[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].

L Chen1, H G Liu1, W Liu2, J Liu3, K Liu1, J Shang1, Y Deng1, S Wei1.   

Abstract

Objective: To analyze the clinical characteristics of 2019 novel coronavirus (2019-nCoV) pneumonia and to investigate the correlation between serum inflammatory cytokines and severity of the disease.
Methods: 29 patients with 2019-ncov admitted to the isolation ward of Tongji hospital affiliated to Tongji medical college of Huazhong University of Science and Technology in January 2020 were selected as the study subjects. Clinical data were collected and the general information, clinical symptoms, blood test and CT imaging characteristics were analyzed. According to the relevant diagnostic criteria, the patients were divided into three groups: mild (15 cases), severe (9 cases) and critical (5 cases). The expression levels of inflammatory cytokines and other markers in the serum of each group were detected, and the changes of these indicators of the three groups were compared and analyzed, as well as their relationship with the clinical classification of the disease.
Results: (1) The main symptoms of 2019-nCoV pneumonia was fever (28/29) with or without respiratory and other systemic symptoms. Two patients died with underlying disease and co-bacterial infection, respectively. (2) The blood test of the patients showed normal or decreased white blood cell count (23/29), decreased lymphocyte count (20/29), increased hypersensitive C reactive protein (hs-CRP) (27/29), and normal procalcitonin. In most patients,serum lactate dehydrogenase (LDH) was significantly increased (20/29), while albumin was decreased(15/29). Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (Tbil), serum creatinine (Scr) and other items showed no significant changes. (3) CT findings of typical cases were single or multiple patchy ground glass shadows accompanied by septal thickening. When the disease progresses, the lesion increases and the scope expands, and the ground glass shadow coexists with the solid shadow or the stripe shadow. (4) There were statistically significant differences in the expression levels of interleukin-2 receptor (IL-2R) and IL-6 in the serum of the three groups (P<0.05), among which the critical group was higher than the severe group and the severe group was higher than the mildgroup. However, there were no statistically significant differences in serum levels of tumor necrosis factor-alpha (TNF-α), IL-1, IL-8, IL-10, hs-CRP, lymphocyte count and LDH among the three groups (P>0.05).
Conclusion: The clinical characteristics of 2019-nCoV pneumonia are similar to those of common viral pneumonia. High resolution CT is of great value in the differential diagnosis of this disease. The increased expression of IL-2R and IL-6 in serum is expected to predict the severity of the 2019-nCoV pneumonia and the prognosis of patients.

Entities:  

Keywords:  2019 novel coronavirus pneumonia; Clinical features; Disease severity; Inflammatory cytokines

Year:  2020        PMID: 32026671     DOI: 10.3760/cma.j.issn.1001-0939.2020.0005

Source DB:  PubMed          Journal:  Zhonghua Jie He He Hu Xi Za Zhi        ISSN: 1001-0939


  156 in total

Review 1.  Familiar dermatologic drugs as therapies for COVID-19.

Authors:  M Ortega-Peña; R González-Cuevas
Journal:  Actas Dermosifiliogr       Date:  2020-12-23

Review 2.  The role of biomarkers in diagnosis of COVID-19 - A systematic review.

Authors:  Muhammed Kermali; Raveena Kaur Khalsa; Kiran Pillai; Zahra Ismail; Amer Harky
Journal:  Life Sci       Date:  2020-05-13       Impact factor: 5.037

3.  [Tracheal intubation in patients with severe and critical COVID-19: analysis of 18 cases].

Authors:  Jiafang Wang; Fan Lu; Mingxing Zhou; Zhong Qi; Zhijun Chen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-03-30

4.  Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases.

Authors:  Aishwarya Mary Johnson; Robert Barigye; Hariharan Saminathan
Journal:  Hum Vaccin Immunother       Date:  2021-05-11       Impact factor: 3.452

5.  Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease.

Authors:  Maheshwar Lakkireddy; Srikanth Goud Gadiga; R D Malathi; Madhu Latha Karra; I S S V Prasad Murthy Raju; Sangeetha Chinapaka; K S S Sai Baba; Manohar Kandakatla
Journal:  Sci Rep       Date:  2021-05-20       Impact factor: 4.996

Review 6.  COVID-19: Is reinfection possible?

Authors:  Aratã Oliveira Cortez Costa; Humberto de Carvalho Aragão Neto; Ana Paula Lopes Nunes; Ricardo Dias de Castro; Reinaldo Nóbrega de Almeida
Journal:  EXCLI J       Date:  2021-03-02       Impact factor: 4.068

7.  NIA-Network: Towards improving lung CT infection detection for COVID-19 diagnosis.

Authors:  Wei Li; Jinlin Chen; Ping Chen; Lequan Yu; Xiaohui Cui; Yiwei Li; Fang Cheng; Wen Ouyang
Journal:  Artif Intell Med       Date:  2021-05-02       Impact factor: 5.326

8.  Ephrin-A1 and the sheddase ADAM12 are upregulated in COVID-19.

Authors:  Rachelle Mendoza; Nayanendu Saha; Amir Momeni; Elmer Gabutan; Mouyed Alawad; Amir Dehghani; John Diks; Bo Lin; Donghai Wang; Mohamed Alshal; William Fyke; Bingcheng Wang; Juha P Himanen; Prem Premsrirut; Dimitar B Nikolov
Journal:  Heliyon       Date:  2021-05-31

Review 9.  Could Nanotheranostics be the Answer to the Coronavirus Crisis?

Authors:  Dina A Mosselhy; Mhd Adel Assad; Tarja Sironen; Mady Elbahri
Journal:  Glob Chall       Date:  2021-03-24

Review 10.  Encapsulated Food Products as a Strategy to Strengthen Immunity Against COVID-19.

Authors:  Soubhagya Tripathy; Deepak Kumar Verma; Mamta Thakur; Ami R Patel; Prem Prakash Srivastav; Smita Singh; Mónica L Chávez-González; Cristobal N Aguilar
Journal:  Front Nutr       Date:  2021-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.